Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml

DRUG4 trials

Sponsors

Amsterdam UMC, Catharina Ziekenhuis Stichting, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Conditions

Borderline resectable pancreatic cancer (BRPC)Pancreatic cancerResectable pancreatic cancer (RPC)colorectal adenocarcinomanon-metastatic (borderline) resectable pancreatic cancer

Phase 1

Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group

RecruitingCTIS2023-508707-20-00

Amsterdam UMCBorderline resectable pancreatic cancer (BRPC), Pancreatic cancer, Resectable pancreatic cancer (RPC)

Start: 2024-09-19Target: 66Updated: 2025-12-15

Phase 2

Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial

RecruitingCTIS2024-510576-21-00

Catharina Ziekenhuis StichtingPancreatic cancer

Start: 2024-09-18Target: 100Updated: 2024-07-09

Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastases. - The PUMP-IT study (M19PIT)

Active, not recruitingCTIS2024-515525-28-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingcolorectal adenocarcinoma

Start: 2020-09-10Target: 31Updated: 2024-11-27

Phase 3

THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

Not yet recruitingCTIS2024-516260-29-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)non-metastatic (borderline) resectable pancreatic cancer

Target: 368Updated: 2024-10-09